コンテンツへスキップ
Merck
  • Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis.

Adrenomedullin inhibits osteoclast differentiation through the suppression of receptor activator of nuclear factor-κB ligand-induced nuclear factor-κB activation in glucocorticoid-induced osteoporosis.

Experimental and therapeutic medicine (2017-10-27)
Yuanxin Liu, Guilai Zuo, Xin Meng, Xingxiao Gao, Lihai Zhang, Peifu Tang
要旨

The current study aimed to improve the understanding on the association between adrenomedullin and osteoporosis in mice with glucocorticoid-induced osteoporosis. Bone resorption and osteoporosis-associated indexes, including maximum load, stiffness, energy to failure, ultimate strength, elastic modulus, post-yield displacement and post-yield displacement, in mice with osteoporosis were analyzed in order to evaluate the effect of adrenomedullin. The receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation was investigated subsequent to treatment with adrenomedullin

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
抗βアクチン−ペルオキシダーゼ抗体、マウスモノクローナル マウス宿主抗体, clone AC-15, purified from hybridoma cell culture
Sigma-Aldrich
Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe, ≥97% (HPLC)
Sigma-Aldrich
Anti-NF-κB p65 antibody produced in rabbit, affinity isolated antibody